



Policy #:	03.99.073
Issued:	March 2022
Reviewed/ Revised:	8/2023, 8/2024
Section:	Nursing

Standing Order - Administration of Topical Anesthetic prior to injection of Sublocade® (buprenorphine extended-release)

Purpose:

To decrease pain from injection of Sublocade® (buprenorphine extended-release) at Boston Medical Center (BMC).

The standing order provides the mechanism for nursing to administer medication per standing order approved by the BMC Medical – Dental Staff. Licensed nurses accept, verify, and implement orders from duly authorized prescribers, including standing orders and protocols.

Pursuant to the Massachusetts Board of Registration in Nursing’s Advisory Ruling 9324, Standing orders/protocols include written authorization from a duly authorized prescriber that indicates evidence-based practice standards for a specific medication or activity to be implemented by the nurse. Standing orders/protocols are applicable to a specific patient or specific situation and directions remain consistent during implementation.

Policy Statement:

Only licensed personnel can administer or supervise the administration of medications within their scope of practice to BMC patients. For the purpose of this policy, topical anesthetic refers to Lidocaine 4% topical cream available in 5 gram tubes. In ambulatory care clinics, the medication is to be administered by the OBAT RN.

Application:

Patients presenting for injection of Sublocade® (buprenorphine extended-release) in the OBAT clinic.

Exceptions:

- OBAT patients receiving injections other than Sublocade® (buprenorphine extended-release).
- Patients known to be allergic to any components of lidocaine.
- Patients with documented rare inherited conditions of porphyria, methemoglobinemia or glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Definitions:

Term	Definition
OBAT	Office Based Addiction Treatment

Procedure:

The OBAT nurse will:

1. Check allergies of patient.
2. Execute standing order for topical 4% lidocaine cream in the EMR.
3. Wash hands and don gloves.

4. Verify identity of the patient by two identifiers and the quadrant Sublocade® (buprenorphine extended-release) is to be administered. Inspect area to ensure skin is intact without any open cuts or wounds.
5. Unless skin is visibly dirty, do not wash the area. If skin needs to be cleaned, use mild soap and water. Do not use alcohol wipes.
6. Point the tube onto the area of skin to be treated and directly squeeze a quarter-sized amount. Do not rub in the medication.
7. Place a plastic dressing over the cream to keep it in place.
8. Make a note of the time of cream application. Topical lidocaine cream takes 20-60 min to become effective.
9. Doff gloves and wash hands with soap and water.

After 20-60 min, begin preparation for injection of Sublocade® (buprenorphine extended-release):

10. Wash hands and don gloves.
11. Remove plastic dressing. Use a sterile gauze to remove any excess medication.
12. Safely dispose of plastic dressing. Skin may appear pale or white after wiping off the medication.
13. Administer Sublocade® (buprenorphine extended-release) per LIP order and according to manufacturer instructions, including skin antisepsis.
14. Document lidocaine and Sublocade® (buprenorphine extended-release) administration on the MAR (Medication Administration Record)

Responsibility:

OBAT RN
OBAT Provider

Forms:

None

Other Related Policies/Protocols/Guidelines:

10.03.010 Medication Administration
03.99.080/13.01.060 Authorization to Administer Medications

References:

1. National Health Service. (August 30, 2022). How and when to use lidocaine skin cream. Retrieved from <https://www.nhs.uk/medicines/lidocaine-skin-cream/how-and-when-to-use-lidocaine-skin-cream/> on July 15, 2024.
2. Boston Children's Hospital (July 20, 2020). Family Education Sheet Numbing Cream to Prepare for a Needle Procedure. Retrieved from <https://extapps.childrenshospital.org/EFPEC/Home/Sheet/1761> on December 16, 2021.

Initiated by: Nursing

Contributing Departments:

OBAT
GIM